Australian respiratory technology company Rhinomed Ltd (ASX:RNO) is pleased to advise it has increased its production line capacity at the ChinaMed production facility.
Rhinomed Limited (ASX:RNO) is a Melbourne, Australia based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is developing and commercialising applications of its technology portfolio in the sport, sleep, cough/cold and allergy, and drug delivery markets. The company has two products in market (the Turbine for sports and exercise and Mute for snoring and better sleep) and has recently completed a pilot Phase I clinical trial of its new INPEAP technology targeting mild to moderate sleep apnea. For more information, go to www.rhinomed.global.
Australian respiratory technology company Rhinomed Ltd (ASX:RNO), is pleased to announce its Mute snoring and sleep technology will be available on pharmacy shelves in the United Kingdom from late October 2015.
Key highlights of the quarter included the growing demand for the company's new Turbine design and strong early demand for the Mute snoring and sleep technology. Receipts from Customers for the quarter were up $33k to $192k. Revenues from the Australian pharmacy channel will be included during the next quarter
2013 Tour de France Yellow Jersey Winner Chris Froome Appointed as Rhinomed Ltd's (ASX:RNO) Turbine Ambassador
Rhinomed Ltd (ASX:RNO) an Australian company focused on the development of novel nasal and respiratory technology today announced 2013 Tour de France Yellow Jersey winner Chris Froome has joined as its new Turbine(TM) Global Ambassador.
Rhinomed Ltd (ASX:RNO) announce the 2015 BIO International Convention Presentation.
Rhinomed Ltd (ASX:RNO), an Australian company focused on the development of novel nasal and respiratory technologies, today announced that it has received Monash Health Human Research Ethics Committee (HREC) approval for its inaugural Phase 1 sleep apnea trial featuring its new Intranasal Positive Expiratory Airway Pressure (INPEAP) technology.
Australian and New Zealand biotech investors are set to hear from a top line up of speakers from ASX-listed life science companies, as well as several private firms and international businesses, in July, at the 11th Bioshares Biotech Summit.
Rhinomed Ltd (ASX:RNO) is pleased to announce that it has been accepted as a presenter at 2015 BIO, the world's leading biotech convention to be held in Philadelphia, June 15-18th.
Australian respiratory technology company Rhinomed Ltd (ASX:RNO) has struck an important sales agreement with global sleep technology heavyweight ResMed Inc (NYSE:RMD) (ASX:RMD) to begin selling the novel Mute(TM) snoring reduction and sleep technology in the key UK market.
Rhinomed (ASX:RNO) is pleased to announce it has continued to expand its Australian wholesale pharmacy distribution footprint with Sigma Pharmaceuticals Limited (ASX:SIP) to wholesale its Mute™ snoring and sleep quality technology.